J&J keeps Alzheimer's focus with Alector collaboration
This article was originally published in Scrip
Executive Summary
Johnson & Johnson entered into a research collaboration with Alector, one of the companies in its biotechnology startup incubator in Northern California, to identify a therapeutic candidate against an undisclosed Alzheimer's disease target.
You may also be interested in...
GSK Looks To Immuno-Neurology In $700m Alector Tie-up
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.